Neuropsychiatric profiles of patients with juvenile myoclonic epilepsy treated with valproate or topiramate

Epilepsy and Behavior

Volumn 8, Issue 3, 2006, Pages 606-609

  de Araujo Filho, Gerardo M ^a   Pascalicchio, Tatiana F ^a   Lin, Katia ^a   Sousa, Patrícia S ^a   Yacubian, Elza M T ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Juvenile myoclonic epilepsy; Neuropsychological tests; Psychiatric disorders; Topiramate; Valproate

Indexed keywords

ANTICONVULSIVE AGENT; TOPIRAMATE; VALPROIC ACID;

ADOLESCENT; ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; BRAIN DISEASE; BRAIN FUNCTION; BRAZIL; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG DOSE REGIMEN; FEMALE; FRONTAL LOBE; HUMAN; INTELLECTUAL IMPAIRMENT; INTERVIEW; LANGUAGE DISABILITY; MALE; MEMORY DISORDER; MENTAL DISEASE; MONOTHERAPY; MOOD DISORDER; MYOCLONUS EPILEPSY; NEUROPSYCHIATRY; PATIENT SELECTION; PREVALENCE; SCHIZOPHRENIA; SHORT TERM MEMORY; SPEECH DISORDER; TASK PERFORMANCE; TONIC CLONIC SEIZURE; VELOCITY; VERBAL BEHAVIOR;

ADOLESCENT; ANTICONVULSANTS; ANXIETY DISORDERS; CROSS-SECTIONAL STUDIES; DEPRESSIVE DISORDER; FEMALE; FRUCTOSE; HUMANS; MALE; MENTAL DISORDERS; MYOCLONIC EPILEPSY, JUVENILE; NEUROPSYCHOLOGICAL TESTS; SEIZURES; VALPROIC ACID;

EID: 33646097220     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2006.01.016     Document Type: Article

References (25)

1. Fernando-Dongas M.C., Radtke R.A., VanLandingham K.E., and Husain A.M. Characteristics of valproic acid resistant juvenile myoclonic epilepsy. Seizure 9 (2000) 385-388
2. Gelisse P., Genton P., and Thomas P. Clinical factors of drug resistance in juvenile myoclonic epilepsy. J Neurol Neurosurg Psychiatry 70 (2001) 240-243
3. Prasad A., Kuzniecky R., Knowlton R.C., et al. Evolving antiepileptic drug treatment in juvenile myoclonic epilepsy. Arch Neurol 60 (2003) 1100-1105
4. Nicolson A., Appleton R.E., Chadwick D.W., and Smith D.F. The relationship between treatment with valproate, lamotrigine and topiramate and the prognosis of idiopathic generalized epilepsies. J Neurol Neurosurg Psychiatry 75 (2004) 75-79
5. Thompson P.J., Baxendale S.A., Duncan J.S., and Sander J.W.A.S. Effects of topiramate on cognitive function. J Neurol Neurosurg Psychiatry 69 (2000) 636-641
6. Meador K.J., Loring D.W., Vahle V.J., et al. Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers. Neurology 64 (2005) 2108-2114
7. Meador K.J., Loring D.W., Hulihan J.F., Kamin M., and Karim R. Differential cognitive and behavioral effects of topiramate and valproate. Neurology 60 (2003) 1483-1488
8. Mula M., and Trimble M.R. The importance of being seizure free: topiramate and psychopathology in epilepsy. Epilepsy Behav 4 (2003) 430-434
9. Davis L.L., Ryan W., Adinoff B., and Petty F. Comprehensive review of the psychiatric uses of valproate. J Clin Psychopharmacol 20 suppl 1 (2000) S1-S17
10. Trimble M.R., Rüsch N., Betts T., and Crawford P.M. Psychiatric symptoms after therapy with new antiepileptic drugs: psychopathological and seizure related variables. Seizure 9 (2000) 249-254
11. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for classification of epilepsies and epileptic syndromes. Epilepsia 1989;30:389-99.
12. Wechsler Adult Intelligence Scale III: technical manual. San Antonio: Psychological Corp.; 1997.
13. First MB, Spitzer PL, Gibbon M, Williams JB. Structured Clinical Interview for DSM-IV axis I disorders: patient edition (SCID-I/P, Version 2.0. 9/98 revision). New York: Biometrics Research Department, New York State Research Institute; 1998.
14. Spitzer PL, Williams JB, Gibbon M, First MB. Structured Clinical Interview for DSM-III-R axis II disorders (SCID-II, Version 9/89). New York: Biometrics Research Department, New York State Research Institute; 1989.
15. Brasil HHA. Desenvolvimento da versão brasileira da K-SADS-PL [Schedule for Affective Disorders and Schizophrenia for School Aged Children Present and Lifetime Version] e estudo de suas propriedades psicométricas [tese de doutorado]. São Paulo: Universidade Federal de São Paulo. Escola Paulista de Medicina. Psiquiatria; 2003.
16. Diagnostic and statistical manual for mental disorders. 4th ed. Revised. Washington, DC: American Psychiatric Association; 2000.
17. Meador K.J., Loring D.W., Moore B.A., et al. Comparative cognitive effects of phenobarbital, phenytoin and valproate in healthy adults. Neurology 45 (1995) 494-499
18. Vermeulen J., and Aldenkamp A.P. Cognitive side-effects of chronic antiepileptic drug treatment: a review of 25 years of research. Epilepsy Res 22 (1995) 65-95
19. Aldenkamp A.P., Baker G., Mulder O.G., et al. A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures. Epilepsia 41 (2000) 1167-1178
20. Mula M., Trimble M.R., Thompson P., and Sander J.W.A. Topiramate and word-finding difficulties in patients with epilepsy. Neurology 60 (2003) 1104-1107
21. Gross-Tsur V., and Shaler R.S. Reversible language regression as an adverse effect of topiramate treatment in children. Neurology 62 (2004) 299-300
22. Devinsky O., Gershengorn J., Brown E., Perrine K., Vazquez B., and Luciano D. Frontal functions in juvenile myoclonic epilepsy. Neuropsychiatry Neuropsychol Behav Neurol 10 (1997) 243-246
23. Jackson M.J., and Turkington D. Depression and anxiety in epilepsy. Neurol Pract 76 Suppl. 1 (2005) i45-i47
24. Gelisse P., Genton P., Samuelian J.-C., Thomas P., and Bureau M. Troubles psychiatriques dans l'épilepsie myoclonique juvenile. Rev Neurol (Paris) 157 (2001) 297-302
25. Perini G.I., Tosin C., Carraro C., et al. Interictal mood and personality disorders in temporal lobe epilepsy and juvenile myoclonic epilepsy. J Neurol Neurosurg Psychiatry 61 (1996) 601-605